Cibus CBUS
NASDAQ CBUS
$1.70 +0.00 (+0.00%)
At close: Aug 20, 2026 · 4:00 PM EDT

Cibus (CBUS) Net Income towards Common Stockholders (2016 - 2026)

Cibus (CBUS) posted Net Income towards Common Stockholders of -$31.9 million for Q4 2025, down 31.46% sequentially from -$24.3 million in Q3 2025, and down 23.81% YoY from -$41.9 million in Q4 2024.

Cibus (CBUS) Net Income towards Common Stockholders (2016 - 2026) Analysis & Trends

Cibus has reported Net Income towards Common Stockholders for 10 years, with the latest figure at -$31.9 million in Q4 2025.

  • Quarterly Net Income towards Common Stockholders fell 23.81% year-over-year to -$31.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$132.2 million (up 53.24% YoY) and the FY2025 annual result came in at -$132.2 million, up 53.24% from the prior year.
  • Net Income towards Common Stockholders declined to -$31.9 million in Q4 2025 per CBUS's latest filing, from -$24.3 million in the prior quarter.
  • Over five years, Net Income towards Common Stockholders peaked at -$2.5 million in Q2 2022 and troughed at -$277.2 million in Q4 2023.
  • A 5-year average of -$39.9 million and a median of -$22.4 million in 2023 frame the typical range for Net Income towards Common Stockholders.
  • The sharpest annual moves came in 2023 and 2024: Net Income towards Common Stockholders plunged 9671.17% in 2023, then soared 90.69% in 2024.
  • Over 5 years, Net Income towards Common Stockholders stood at -$7.1 million in 2021, then soared by 59.8% to -$2.8 million in 2022, then slumped by 9671.17% to -$277.2 million in 2023, then jumped by 90.69% to -$25.8 million in 2024, then declined by 23.81% to -$31.9 million in 2025.
  • According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$31.9 million, -$24.3 million, and -$26.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Vertex Pharmaceuticals 137.11 Bn 129.26 Bn 2.84 Bn 1.10 Bn
2 Regeneron Pharmaceuticals 84.98 Bn 76.99 Bn 3.93 Bn 1.30 Bn
3 Argenx Se 64.52 Bn 59.33 Bn 1.37 Bn 472.00 Mn
4 Moderna 53.23 Bn 48.09 Bn 52.00 Mn -782.00 Mn
5 BeOne Medicines 41.23 Bn 36.14 Bn 1.53 Bn 237.01 Mn
6 Alnylam Pharmaceuticals 30.65 Bn 27.34 Bn 992.69 Mn 164.49 Mn
7 Insmed 27.15 Bn 25.99 Bn 358.27 Mn -13.27 Mn
8 Royalty Pharma 26.98 Bn 26.14 Bn - 81.49 Mn
9 BioNTech SE 26.78 Bn 8.39 Bn 668.28 Mn -174.37 Mn
10 Cibus 131.25 Mn 110.82 Mn - -22.15 Mn

Historic Data

Download Data
DateValue
Jun 30, 2026 -22.15 Mn
Dec 31, 2025 -31.95 Mn
Sep 30, 2025 -24.30 Mn
Jun 30, 2025 -26.56 Mn
Mar 31, 2025 -49.39 Mn
Dec 31, 2024 -25.80 Mn
Sep 30, 2024 -201.46 Mn
Jun 30, 2024 -28.48 Mn
Mar 31, 2024 -26.97 Mn
Dec 31, 2023 -277.21 Mn
Sep 30, 2023 -34.53 Mn
Jun 30, 2023 -20.51 Mn
Mar 31, 2023 -5.39 Mn
Dec 31, 2022 -2.84 Mn
Sep 30, 2022 -5.95 Mn
Jun 30, 2022 -2.49 Mn
Mar 31, 2022 -5.62 Mn
Dec 31, 2021 -7.06 Mn
Sep 30, 2021 -7.31 Mn
Jun 30, 2021 -4.81 Mn